NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NDA FilingPrimeCPositive

AI Analysis

Summary

NeuroSense Therapeutics completed the Pre-NDS process with Health Canada for its ALS drug PrimeC, with alignment achieved on submission content and structure. The company plans to file with Health Canada in December 2026.

Outcome Details

Completed Pre-NDS process meeting with Health Canada; advancing toward submission

Importance:6/10

Sentiment:

0.60

regulatory milestoneHealth CanadaALSNDS filinglate-stage

Related Companies

$NRSN $HIT

Read the original article

Published by PR Newswire Pharma on August 6, 2026 3:29 PM

Read Original